S
Structure Therapeutics
Biotech & Life Sciences · South San Francisco, United States · Founded 2016 · IPO 2023
Specializes in the discovery and development of drugs against a type of targets called GPCR MoreLess
Structure Therapeutics is a clinical-stage biopharmaceutical company that specializes in the discovery and development of oral small molecule therapeutics for the treatment of chronic metabolic diseases. The company leverages its expertise in structure-based drug design to create more accessible and effective treatments.
Operating in the biopharmaceutical market, Structure Therapeutics focuses on developing innovative drugs for a range of metabolic disorders. Its business model is centered on a science-driven approach to drug discovery, advancing promising candidates through clinical trials. The company generates revenue through the development and commercialization of its proprietary drug candidates.
Keywords: biopharmaceutical, clinical-stage, drug design, metabolic diseases, oral therapeutics, small molecules, structure-based, GLP-1, GPCR, chronic illness
Talent graph
Structure Therapeutics's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Structure Therapeutics has talent and traffic
team presence
across markets
Market sentiment
What the market is saying about Structure Therapeutics
An AI-synthesized read of the highest-engagement posts about Structure Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Structure Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.